TrialAntimicrobial agents and chemotherapy2004

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.

T M File et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.